7th Global Gastroenterology and Artificial Intelligence Summit (Live) | September 2025-2025 7Th Global Ai Summit And Workshop Panel Discusssion 2

Video Transcription

Video Summary

The discussion addresses key issues surrounding AI in healthcare, focusing on intellectual property (IP), regulation, liability, and reimbursement. Shannon explains that IP rights for physicians contributing data to AI are currently unsettled and largely depend on contractual terms, with no clear legal protections. Regarding liability, the risk of being sued for not using AI depends on whether AI tools become the standard of care, which varies by specialty and readiness of AI technology. Regulatory distinctions exist between AI tools developed and used internally by hospitals versus those commercialized; FDA oversight applies if tools meet the medical device definition. Online AI tools without specific healthcare indications remain largely unregulated, raising safety concerns. Kristen highlights reimbursement challenges—AI tools improving workflow are not billable, whereas regulated digital therapeutics for home use can be reimbursed. Industry representatives emphasize that regulatory clarity and payer support are critical to broader AI adoption, with current regulatory demands, especially for U.S. trials, slowing market entry despite clinical evidence and approvals elsewhere.

Keywords

AI in healthcare

intellectual property rights

liability and standard of care

FDA regulation of AI tools

reimbursement challenges for AI